Goldline Pharmaceutical IPO Details
Goldline Pharmaceutical IPO Summary
Goldline Pharmaceutical IPO DRHP (Draft Red Herring Prospectus) has been Exchange Approval Received.
Goldline Pharmaceutical IPO total issue size comprises 30,00,000 shares (aggregating up to ₹0.00 Cr.). This includes a fresh issue of 30,00,000 shares (aggregating up to ₹0.00 Cr.). Pre-issue shareholding stands at 69,00,000, which will increase to 99,00,000 post-issue.
Goldline Pharmaceutical IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
The Lead Managers for Goldline Pharmaceutical IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Cumulative Capital Pvt Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Goldline Pharmaceutical Limited DRHP.
Goldline Pharmaceutical IPO Details
Goldline Pharmaceutical IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| To be announced | |||
Goldline Pharmaceutical IPO Reservation
Promoter Holding
Documents
Goldline Pharmaceutical IPO Valuations
Goldline Pharmaceutical Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 26.28 | 22.93 | 19.39 |
| Total Income | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.83 | 1.81 | 0.26 |
| EBITDA | 5.83 | 4.30 | 2.19 |
| NET Worth | 10.35 | 7.87 | 5.89 |
| Reserves and Surplus | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 11.03 | 11.13 | 10.83 |
| Amount in ₹ Crore | |||
About Goldline Pharmaceutical IPO
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments:
- Goldline Pharma: This category includes 42 products to cater to specialties like Physicians, Orthopedics, ENT, Chest Physicians, General and Specialty Surgery, Gastroenterology, Neurology, and Urology.
- Goldline Cardinal: This category offers 54 products tailored for the Specialty division, serving medical fields such as Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians.
- Goldline Aayushman: This category comprises 18 products designed for the Specialty division, catering to medical fields such as Pediatricians, Child Specialists, Neonatologists, and General Practitioners.
- Goldline InLife: This category includes 22 products tailored for the Specialty division, serving Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians.
- Goldline Wellness: This category includes 10 products tailored Supportive care plays a crucial role in cancer therapy.
The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations.
All products are marketed and sold under the Goldline brand through our network of distributors, who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors, and it also support hospitals and healthcare providers with procurement and material supply.
The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Competitive Strengths:
- Experienced Promoters and Management Team with Industry Knowledge and a Track Record
- Asset-light Business Model and Competitive Products
- Scalable Business Model
- Wide and Diverse Range of Product Offerings
- Strong Supplier and Vendor Relationships
- Established Distribution Network
Strength Of Goldline Pharmaceutical IPO
Risk Of Goldline Pharmaceutical IPO
Objectives Goldline Pharmaceutical IPO
1. Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company
2. General corporate purposes
Company Contact Details
Goldline Pharmaceutical Ltd.
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Phone: +91 712 2786666
Email: info@goldlinepharma.in
Website: http://www.goldlinepharma.in/
Registrar Contact Details
Market Maker
Goldline Pharmaceutical FAQs
The Goldline Pharmaceutical IPO is a SME public issue comprising 3000000 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹0.00 Cr.. The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
Bigshare Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the BSE
As of now, the current GMP stands at TBA.
Quick Links
Comments
